Formulation of rifampicin softpellets for high dose delivery to the lungs with a novel high dose dry powder inhaler.

[1]  H. Jenkins,et al.  Shedding Light on Tuberculosis Deaths in Children and Adolescents , 2021, Pediatrics.

[2]  H. Frijlink,et al.  Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility , 2020, Pharmaceutics.

[3]  K. Schepanski,et al.  Enhanced tenacity of mycobacterial aerosols from necrotic neutrophils , 2020, Scientific Reports.

[4]  D. T. Loots,et al.  Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. , 2020, Toxicology letters.

[5]  E. Netto,et al.  Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis , 2019, PloS one.

[6]  S. Ekins,et al.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs , 2019, Pharmaceutical Research.

[7]  Madhukar Pai,et al.  Tuberculosis , 2019, The Lancet.

[8]  P. Young,et al.  Dosing challenges in respiratory therapies , 2018, International journal of pharmaceutics.

[9]  S. Anderson.  Repurposing drugs as inhaled therapies in asthma , 2018, Advanced drug delivery reviews.

[10]  R. Reves,et al.  Latent tuberculosis infection: Opportunities and challenges , 2018, Respirology.

[11]  P. Young,et al.  Drug delivery for tuberculosis: is inhaled therapy the key to success? , 2017, Therapeutic delivery.

[12]  E. Nardell,et al.  Inhaled drug treatment for tuberculosis: Past progress and future prospects. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[13]  H. Smyth,et al.  Carrier-free high-dose dry powder inhaler formulation of ibuprofen: Physicochemical characterization and in vitro aerodynamic performance. , 2016, International journal of pharmaceutics.

[14]  R. Chaisson,et al.  Latent Mycobacterium tuberculosis infection. , 2015, The New England journal of medicine.

[15]  H. Chan,et al.  Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis , 2015, Drug development and industrial pharmacy.

[16]  C. Peloquin,et al.  Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update , 2014, Drugs.

[17]  TrainiDaniela,et al.  Overcoming Dose Limitations Using the Orbital® Multi-Breath Dry Powder Inhaler , 2014 .

[18]  Wanda Cruz-Knight,et al.  Tuberculosis: an overview. , 2013, Primary care.

[19]  A. Chuchalin,et al.  Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial , 2013, Current medical research and opinion.

[20]  D. Raoult,et al.  Soluble squalamine tablets for the rapid disinfection of home nebulizers of cystic fibrosis patients. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[21]  G. Döring,et al.  Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study , 2012, Thorax.

[22]  H. Frijlink,et al.  Characterisation of high dose aerosols from dry powder inhalers. , 2012, International journal of pharmaceutics.

[23]  Nazrul Islam,et al.  Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery--a review for multidisciplinary researchers. , 2012, Medical engineering & physics.

[24]  A H de Boer,et al.  A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? , 2012, Advanced drug delivery reviews.

[25]  J. Weers,et al.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. , 2011, Journal of aerosol medicine and pulmonary drug delivery.

[26]  Brian G. Williams,et al.  Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review , 2011, PloS one.

[27]  S. Bihari,et al.  Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum. , 2008, Journal of postgraduate medicine.

[28]  B. Alisjahbana,et al.  Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients , 2007, Antimicrobial Agents and Chemotherapy.

[29]  D. Geller.  Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. , 2005, Respiratory care.

[30]  S. Newman,et al.  Principles of metered-dose inhaler design. , 2005, Respiratory care.

[31]  A. Hickey,et al.  Dry powder inhaler formulation. , 2005, Respiratory care.

[32]  N. Rasenack,et al.  In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate. , 2003, International journal of pharmaceutics.

[33]  W. Finlay,et al.  Deagglomeration of dry powder pharmaceutical aerosols. , 2002, International journal of pharmaceutics.

[34]  C. Newcomer,et al.  Airways delivery of rifampicin microparticles for the treatment of tuberculosis. , 2001, The Journal of antimicrobial chemotherapy.

[35]  C. Newcomer,et al.  Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model , 2001, Pharmaceutical Research.

[36]  Anthony J. Hickey,et al.  Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Manufacture and Characterization , 2000, Pharmaceutical Research.

[37]  C. Peloquin.  Therapeutic Drug Monitoring in the Treatment of Tuberculosis , 2012, Drugs.

[38]  M. Konstan,et al.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[39]  H. Frijlink,et al.  5 Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept ( Twincer ® ) for high powder doses , 2009 .